科微学术

生物工程学报

2025年4月6日 7:37 星期日
首页 > 过刊浏览>2024年第40卷第2期 >585-595. DOI:10.13345/j.cjb.230619
PDF HTML阅读 XML下载 导出引用 引用提醒
溶瘤Ⅱ型单纯疱疹病毒在肿瘤中的复制及表达
作者:

Replication and expression of oncolytic herpes simplex virus type Ⅱ in tumors
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [38]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    本研究旨在检测BALB/c小鼠肿瘤注射部位溶瘤Ⅱ型单纯疱疹病毒(oncolytic herpes simplex virus type 2, oHSV2)的持续时间和复制水平。同时检测血清中人粒细胞-巨噬细胞集落刺激因子(human granulocyte macrophage colony-stimulating factor, hGM-CSF)的表达量和HSV-2抗体水平。小鼠经瘤内注射高、低两个剂量oHSV2-Fluc[萤火虫荧光素酶(firefly luciferase, Fluc)]，检测其荧光表达变化及持续时间。采用实时荧光定量聚合酶链式反应(quantitative real-time polymerase chain reaction, qPCR)检测肿瘤组织中oHSV2基因拷贝数。酶联免疫吸附法(enzyme linked immunosorbent assay, ELISA)检测血清中hGM-CSF表达量以及HSV-2抗体水平。结果表明高剂量组肿瘤体积显著小于对照组(P<0.01)。瘤内注射oHSV2-Fluc表明病毒携带的Fluc可以在肿瘤中持续表达，于第11天仍能检测到荧光，直至第18天低于检测线。通过提取肿瘤组织RNA进行qPCR，表明第9天高、低剂量组肿瘤组织均存在oHSV2的mRNA。对血清进行ELISA检测，相较于对照组，高、低剂量组hGM-CSF及HSV2抗体水平显著提高(P<0.05)。这些发现表明，oHSV2能够在瘤内正常复制，同时所携带的外源因子可持续表达，对肿瘤产生杀伤作用。瘤内注射oHSV2后，小鼠血清中存在较高水平的hGM-CSF和HSV-2抗体。

    Abstract:

    This study aimed to measure the duration and replication level of oncolytic herpes simplex virus type 2 (oHSV2) at the tumor injection site in BALB/c mice. Additionally, the expression level of human granulocyte macrophage colony-stimulating factor (hGM-CSF) and HSV-2 antibody in the serum was also measured. High and low doses of oHSV2-Fluc (firefly luciferin, Fluc) were injected into the mice’s tumors to track the change and duration of fluorescence expression. The copy number of oHSV2 gene in tumor tissues was determined using quantitative real-time polymerase chain reaction (qPCR). Enzyme linked immunosorbent assay (ELISA) was used to detect the expression of hGM-CSF and HSV-2 antibody in the serum. The tumor volume in the high-dose group was significantly lower than that in the control group (P<0.01). Intratumor injection of oHSV2-Fluc showed that the carried Fluc could continue to express in the tumor, with fluorescence still detectable at day 11 and declining to undetectable level by day 18. The mRNA expression of oHSV2 was detected in tumor tissues of both high and low dose groups on day 9 using qPCR. ELISA results showed that the levels of HSV2 antibody and hGM-CSF in both high and low dose groups were significantly increased compared to the control group (P<0.05) after collecting orbital blood. These findings suggest that oHSV2 can replicate in the tumor and sustainably express exogenous factors, thus effectively targeting and killing the tumor. Furthermore, intratumoral injection of oHSV2 resulted in higher levels of hGM-CSF and HSV-2 antibodies found in the mice’s serum.

    参考文献
    [1] XIA CF, DONG XS, LI H, CAO MM, SUN DQ, HE SY, YANG F, YAN XX, ZHANG SL, LI N, CHEN WQ. Cancer statistics in China and United States, 2022:profiles, trends, and determinants[J]. Chinese Medical Journal, 2022, 135(5):584-590.
    [2] VERKUIJL SJ, JONKER JE, TRZPIS M, BURGERHOF JGM, BROENS PMA, FURNÉE EJB. Functional outcomes of surgery for colon cancer:a systematic review and meta-analysis[J]. European Journal of Surgical Oncology, 2021, 47(5):960-969.
    [3] RALLIS KS, YAU THL, SIDERIS M. Chemoradiotherapy in cancer treatment:rationale and clinical applications[J]. Anticancer Research, 2021, 41(1):1-7.
    [4] GALON J, BRUNI D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nature Reviews Drug Discovery, 2019, 18(3):197-218.
    [5] KRAEHENBUEHL L, WENG CH, EGHBALI S, WOLCHOK JD, MERGHOUB T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways[J]. Nature Reviews Clinical Oncology, 2022, 19(1):37-50.
    [6] SPOLSKI R, LI P, LEONARD WJ. Biology and regulation of IL-2:from molecular mechanisms to human therapy[J]. Nature Reviews Immunology, 2018, 18(10):648-659.
    [7] HERNANDEZ R, PÕDER J, LaPORTE KM, MALEK TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer[J]. Nature Reviews Immunology, 2022, 22(10):614-628.
    [8] KAMADA T, TOGASHI Y, TAY C, HA D, SASAKI A, NAKAMURA Y, SATO E, FUKUOKA S, TADA Y, TANAKA A, MORIKAWA H, KAWAZOE A, KINOSHITA T, SHITARA K, SAKAGUCHI S, NISHIKAWA H. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J]. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(20):9999-10008.
    [9] SCHUBERT ML, SCHMITT M, WANG L, RAMOS CA, JORDAN K, MÜLLER-TIDOW C, DREGER P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy[J]. Annals of Oncology:Official Journal of the European Society for Medical Oncology, 2021, 32(1):34-48.
    [10] ŠPANIELOVÁ H, BRDIČKA R. Oncolytic viruses and cancer treatment[J]. Klinicka Onkologie, 2023, 36(1):12-27.
    [11] YE K, LI F, WANG RK, CEN TY, LIU SY, ZHAO ZQ, LI RN, XU LL, ZHANG GM, XU ZY, DENG L, LI LL, WANG W, STEPANOV A, WAN YJ, GUO Y, LI YK, WANG Y, TIAN YJ, GABIBOV AG, et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ[J]. Molecular Therapy:the Journal of the American Society of Gene Therapy, 2022, 30(12):3658-3676.
    [12] MOHR P, HAFERKAMP S, PINTER A, WEISHAUPT C, HUBER MA, DOWNEY G, ÖHRLING K, LOQUAI C, LOUIE KS. Real-world use of talimogene laherparepvec in German patients with stage IIIB to IVM1a melanoma:a retrospective chart review and physician survey[J]. Advances in Therapy, 2019, 36(1):101-117.
    [13] FRAMPTON JE. Teserpaturev/G47Δ:first approval[J]. BioDrugs:Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 2022, 36(5):667-672.
    [14] NAKATAKE R, KAIBORI M, NAKAMURA Y, TANAKA Y, MATUSHIMA H, OKUMURA T, MURAKAMI T, INO Y, TODO T, KON M. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice[J]. Cancer Science, 2018, 109(3):600-610.
    [15] de CLERCQ E. Selective anti-herpesvirus agents[J]. Antiviral Chemistry and Chemotherapy, 2013, 23(3):93-101.
    [16] 施桂兰, 庄秀芬, 韩香萍, 李洁, 张郁, 张叔人, 刘滨磊. 新型溶瘤病毒oHSV2hGM-CSF的构建及其抗肿瘤作用[J]. 中华肿瘤杂志, 2012, 34(2):89-95. SHI GL, ZHUANG XF, HAN XP, LI J, ZHANG Y, ZHANG SR, LIU BL. Construction of a novel oncolytic virus oHSV2hGM-CSF and its antitumor effect[J]. Chinese Journal of Cancer, 2012, 34(2):89-95(in Chinese).
    [17] LIU BL, ROBINSON M, HAN ZQ, BRANSTON RH, ENGLISH C, REAY P, McGRATH Y, THOMAS SK, THORNTON M, BULLOCK P, LOVE CA, COFFIN RS. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties[J]. Gene Therapy, 2003, 10(4):292-303.
    [18] CHENG JT, WANG YY, ZHU LZ, ZHANG Y, CAI WQ, HAN ZW, ZHOU Y, WANG XW, PENG XC, XIANG Y, YANG HY, CUI SZ, MA ZW, LIU BR, XIN HW. Novel transcription regulatory sequences and factors of the immune evasion protein ICP47(US12) of herpes simplex viruses[J]. Virology Journal, 2020, 17:1-11.
    [19] HU H, ZHANG SQ, CAI LK, DUAN HX, LI YY, YANG JH, WANG Y, LIU B, DONG S, FANG ZZ, LIU BL. A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7×CCL19 results in enhanced antitumor efficacy[J]. Virology Journal, 2022, 19(1):1-12.
    [20] GHOSE J, DONA A, MURTADHA M, GUNES EG, CASERTA E, YOO JY, RUSSELL L, JAIME-RAMIREZ AC, BARWICK BG, GUPTA VA, SANCHEZ JF, SBOROV DW, ROSEN ST, KRISHNAN A, BOISE LH, KAUR B, HOFMEISTER CC, PICHIORRI F. Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo[J]. Molecular Therapy-Oncolytics, 2021, 20:519-531.
    [21] SGUBIN D, WAKIMOTO H, KANAI R, RABKIN SD, MARTUZA RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells[J]. Stem Cells Translational Medicine, 2012, 1(4):322-332.
    [22] ZHANG W, HU X, LIANG J, ZHU YJ, ZENG BB, FENG L, ZHAO CY, LIU SM, LIU BL, ZHANG KT. oHSV2 can target murine colon carcinoma by altering the immune status of the tumor microenvironment and inducing antitumor immunity[J]. Molecular Therapy-Oncolytics, 2020, 16:158-171.
    [23] ZHANG W, WANG FF, HU X, LIANG J, LIU BL, GUAN Q, LIU SM. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity[J]. Oncology Letters, 2018:815-822.
    [24] YIN L, ZHAO CH, HAN JX, LI ZJ, ZHEN YN, XIAO RX, XU ZF, SUN YL. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo[J]. Therapeutics and Clinical Risk Management, 2017, 13:117-130.
    [25] KONG DF, YANG ZR, LI GL, WU QY, GU ZR, WAN D, ZHANG Q, ZHANG XL, CHENG SJ, LIU BL, ZHANG KT, ZHANG W. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment[J]. BMC Medicine, 2022, 20:376.
    [26] WU QY, HU X, ZHANG XL, KONG DF, YANG ZR, LI GL, GU ZR, ZHANG Q, WAN D, CHENG SJ, LIU BL, ZHANG KT, ZHANG W. Single-cell transcriptomics of peripheral blood reveals anti-tumor systemic immunity induced by oncolytic virotherapy[J]. Theranostics, 2022, 12(17):7371-7389.
    [27] WANG Y, ZHOU XB, WU Z, HU H, JIN J, HU YP, DONG YT, ZOU JW, MAO ZY, SHI XT, HUO Y, LYU JJ, FANG ZZ, ZHANG W, ZHU YJ, LI B, LIU BL. Preclinical safety evaluation of oncolytic herpes simplex virus type 2[J]. Human Gene Therapy, 2019, 30(5):651-660.
    [28] ZHANG B, HUANG J, TANG JL, HU S, LUO SX, LUO ZG, ZHOU FX, TAN SY, YING JE, CHANG Q, ZHANG R, GENG CY, WU DW, GU XY, LIU BL. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors:a multicenter, phase Ⅰ/Ⅱ clinical trial[J]. Journal for Immunotherapy of Cancer, 2021, 9(4):e002224.
    [29] WATANABE M, OTAKE R, KOZUKI R, TOIHATA T, TAKAHASHI K, OKAMURA A, IMAMURA Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surgery Today, 2020, 50(1):12-20.
    [30] HUANG ZJ, GUO HE, LIN L, LI SX, YANG Y, HAN YY, HUANG WW, YANG JL. Application of oncolytic virus in tumor therapy[J]. Journal of Medical Virology, 2023, 95(4):e28729.
    [31] KAUFMAN HL, BINES SD. OPTIM trial:a phase Ⅲ trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage Ⅲ or Ⅳ melanoma[J]. Future Oncology (London, England), 2010, 6(6):941-949.
    [32] YANG LD, GU X, YU J, GE SF, FAN XQ. Oncolytic virotherapy:from bench to bedside[J]. Frontiers in Cell and Developmental Biology, 2021, 9:790150.
    [33] NAKAO S, ARAI Y, TASAKI M, YAMASHITA M, MURAKAMI R, KAWASE T, AMINO N, NAKATAKE M, KUROSAKI H, MORI M, TAKEUCHI M, NAKAMURA T. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade[J]. Science Translational Medicine, 2020, 12(526):eaax7992.
    [34] KAUFMAN HL, KOHLHAPP FJ, ZLOZA A. Oncolytic viruses:a new class of immunotherapy drugs[J]. Nature Reviews Drug Discovery, 2015, 14(9):642-662.
    [35] VITIELLO GAF, FERREIRA WAS, CORDEIRO de LIMA VC, da SILVA MEDINA T. Antiviral responses in cancer:boosting antitumor immunity through activation of interferon pathway in the tumor microenvironment[J]. Frontiers in Immunology, 2021, 12:782852.
    [36] GOMES T, TEICHMANN SA. An antiviral response beyond immune cells[J]. Nature, 2020, 583(7815):206-207.
    [37] LI LZ, LIU SX, HAN DD, TANG B, MA J. Delivery and biosafety of oncolytic virotherapy[J]. Frontiers in Oncology, 2020, 10:475.
    [38] ZHANG B, CHENG P. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy[J]. Molecular Cancer, 2020, 19(1):1-16.
    引证文献
引用本文

蔡奇应,张思琪,刘华鹃,刘滨磊. 溶瘤Ⅱ型单纯疱疹病毒在肿瘤中的复制及表达[J]. 生物工程学报, 2024, 40(2): 585-595

复制
分享
文章指标
  • 点击次数:315
  • 下载次数: 987
  • HTML阅读次数: 393
  • 引用次数: 0
历史
  • 收稿日期:2023-09-08
  • 最后修改日期:2023-11-16
  • 在线发布日期: 2024-01-26
  • 出版日期: 2024-02-25
文章二维码
您是第位访问者
生物工程学报 ® 2025 版权所有

通信地址：中国科学院微生物研究所    邮编：100101

电话：010-64807509   E-mail：cjb@im.ac.cn

技术支持：北京勤云科技发展有限公司